Cooper Companies Posts 15% EPS Gain

Cooper Companies (NASDAQ:COO), a global medical device maker specializing in vision care and women’s health, reported its third quarter fiscal 2025 results on August 27, 2025. The results highlighted a notable slowdown in underlying sales growth, with revenue of $1,060.3 million (GAAP), coming in below market expectations. Organic revenue growth cooled to 2% from 7% in the prior quarter. On the other hand, non-GAAP profitability outpaced expectations, with non-GAAP earnings per share reaching $1.10, a 15% year-over-year gain in non-GAAP EPS. Gross margin climbed to 67% on a non-GAAP basis, a 1.0 percentage point improvement in non-GAAP gross margin. Despite subdued top-line growth, management raised full-year non-GAAP EPS guidance while tightening revenue forecasts, citing operational efficiency and cost controls as key drivers for improved profitability this period. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report. Cooper Companies operates two main business lines: CooperVision, which produces specialized contact lenses, and CooperSurgical, which focuses on women’s health products such as surgical devices and fertility treatments. The company is known for innovation in eye care, especially daily disposable lenses using materials like silicone hydrogel, and in launching products for managing conditions such as myopia in children.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool